US · TECH
Bio-Techne Corporation
- Sector
- Healthcare · Biotechnology
- Headquarters
- Minneapolis, MN 55413
- Website
- bio-techne.com
Price · as of 2025-06-30
$55.02
Market cap 9.23B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $47.73 | -13.25% |
| Intrinsic Value(DCF) | $21.70 | -60.56% |
| Graham-Dodd Method(GD) | $3.49 | -93.67% |
| Graham Formula(GF) | $6.11 | -88.9% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $15.31 | $32.27 | $1.46 | $3.14 | $11.80 |
| 2012 | $16.00 | $32.98 | $1.45 | $3.62 | $12.29 |
| 2013 | $17.30 | $32.56 | $2.87 | $3.83 | $5.33 |
| 2014 | $21.90 | $36.26 | $5.20 | $3.51 | $17.05 |
| 2015 | $21.51 | $36.72 | $6.50 | $1.94 | $24.24 |
| 2016 | $25.08 | $36.03 | $6.85 | $1.73 | $12.70 |
| 2017 | $28.68 | $37.59 | $9.58 | $0.32 | $10.55 |
| 2018 | $46.17 | $45.95 | $5.20 | $2.59 | $18.16 |
| 2019 | $45.71 | $47.41 | $3.93 | $1.24 | $11.86 |
| 2020 | $60.14 | $53.94 | $0.00 | $6.97 | $17.08 |
| 2021 | $126.65 | $89.24 | $10.47 | $4.37 | $29.90 |
| 2022 | $85.26 | $74.17 | $20.22 | $9.48 | $45.28 |
| 2023 | $70.91 | $60.37 | $4.56 | $11.23 | $19.62 |
| 2024 | $70.92 | $56.01 | $0.00 | $7.49 | $10.71 |
| 2025 | $54.26 | $47.73 | $0.00 | $3.48 | $6.11 |
AI valuation
Our deep-learning model estimates Bio-Techne Corporation's (TECH) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $47.73
- Current price
- $55.02
- AI upside
- -13.25%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$21.70
-60.56% upside
Graham-Dodd
$3.49
-93.67% upside
Graham Formula
$6.11
-88.9% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| TECH | Bio-Techne Corporation | $55.02 | 9.23B | -13% | -61% | -94% | -89% | 116.45 | 4.45 | 7.01 | 40.71 | — | 14.94 | 64.80% | 8.38% | 6.02% | 3.68% | 3.36% | 2.79% | 0.23 | 12.02 | 3.46 | 2.10 | 1.30 | -5619.00% | 523.00% | 866.00% | 3.00% | 1.64 | 11.31% | 0.59% | 68.70% | 3.82% | 86.35 | 34.42 | 7.24 | 9.42 |
| BMRN | BioMarin Pharmaceutical I… | $61.73 | 11.86B | +37% | -52% | -36% | -40% | 32.84 | 1.88 | 3.56 | 18.32 | — | 2.02 | 77.13% | 16.56% | 10.83% | 5.94% | 7.50% | 4.79% | 0.10 | 48.95 | 5.21 | 3.25 | -1.25 | -1855.00% | 1287.00% | 5249.00% | 6.33% | 1.09 | 14.09% | 0.00% | 0.00% | 3.68% | 19.67 | 14.48 | 3.26 | 5.75 |
| CAI | Caris Life Sciences, Inc. | $20.14 | 5.68B | +132% | +659% | — | — | -507.35 | 59.84 | 42.54 | 2965.27 | — | 61.91 | 66.40% | 5.56% | -66.25% | 7.09% | -3.82% | -9.27% | 0.00 | 0.79 | 7.85 | 7.17 | -70.09 | -2963.00% | 9697.00% | -12637.00% | 0.19% | 0.65 | -5.66% | 0.00% | 0.00% | 3.35% | 748.01 | 504.44 | 41.56 | 36.41 |
| CORT | Corcept Therapeutics Inco… | $35.70 | 3.8B | +198% | +64% | -69% | -45% | 38.06 | 5.77 | 4.91 | 49.30 | — | 5.77 | 98.30% | 5.88% | 13.09% | 14.79% | 15.32% | 11.71% | 0.01 | — | 2.92 | 2.60 | -1.67 | -3333.00% | 1279.00% | -2762.00% | 3.80% | 0.85 | 48.48% | 0.00% | 0.00% | 6.58% | 75.23 | 23.77 | 4.43 | 14.49 |
| EXEL | Exelixis, Inc. | $44.06 | 11.81B | +59% | -51% | -50% | -3% | 14.24 | 5.16 | 4.80 | 11.13 | 24.57 | 5.31 | 96.39% | 37.59% | 33.73% | 35.53% | 55.80% | 27.02% | 0.08 | — | 3.56 | 3.32 | -0.34 | 5795.00% | 698.00% | 3322.00% | 7.58% | 2.18 | 64.97% | 0.00% | 0.00% | 11.04% | 11.76 | 12.15 | 4.42 | 12.01 |
| JAZZ | Jazz Pharmaceuticals plc | $190.02 | 11.7B | -5% | -56% | -94% | — | -32.61 | 2.69 | 2.72 | 104.22 | — | -5.99 | 88.21% | 5.26% | -8.35% | -8.47% | 2.26% | -3.01% | 0.25 | 1.15 | 1.86 | 0.99 | -2.87 | -16751.00% | 488.00% | -377.00% | 11.17% | 0.60 | 23.02% | 0.00% | 0.00% | 36.04% | 50.37 | 8.72 | 2.65 | 1.65 |
| MDGL | Madrigal Pharmaceuticals,… | $432.00 | 9.81B | -42% | +134,896% | — | — | -33.90 | 16.22 | 10.20 | -34.57 | — | 16.42 | 94.14% | -31.31% | -30.08% | -42.49% | 761.60% | -25.05% | 0.59 | -13.45 | 4.01 | 3.60 | -0.59 | -4132.00% | 43205.00% | -5842.00% | -1.94% | -0.61 | 482.24% | 0.00% | 0.00% | 0.00% | -30.47 | -48.12 | 9.54 | 7.47 |
| MRNA | Moderna, Inc. | $53.57 | 20.93B | -39% | -52% | — | +298% | -7.28 | 2.38 | 10.57 | -6.53 | — | 2.38 | 55.35% | -158.13% | -145.16% | -28.87% | -65.47% | -21.31% | 0.22 | — | 3.29 | 3.01 | 0.27 | -2168.00% | -3923.00% | -4908.00% | -10.05% | -0.94 | -43.98% | 0.00% | 0.00% | 0.00% | -5.42 | -8.07 | 8.58 | 3.94 |
| QGEN | Qiagen N.V. | $49.80 | 10.26B | +6% | -52% | -77% | -45% | 23.90 | 2.69 | 4.86 | 14.93 | 5.47 | 14.69 | 61.79% | 24.90% | 20.33% | 11.57% | 10.79% | 7.09% | 0.44 | 15.65 | 3.90 | 2.93 | 1.14 | 43684.00% | 565.00% | -1049.00% | 4.46% | 1.28 | 10.85% | 0.53% | 12.80% | 1.82% | 20.58 | 23.63 | 5.12 | 3.92 |
| RNA | Avidity Biosciences, Inc. | $14.75 | 2.28B | +47% | -35% | — | — | -3.00 | 1.22 | 109.48 | -0.66 | -4.17 | 1.22 | 77.87% | -3977.30% | -3650.39% | -43.98% | -9010.06% | -38.88% | 0.06 | — | 9.20 | 8.75 | 0.42 | 7197.00% | 7211.00% | 11555.00% | -32.33% | -3.33 | -8017.39% | 0.00% | 0.00% | 3.65% | -0.60 | -0.68 | 24.04 | 3.18 |
| RVMD | Revolution Medicines, Inc… | $102.02 | 19.72B | — | — | — | — | -17.08 | 11.84 | — | -16.01 | -25.80 | 12.38 | 0.00% | — | — | -58.07% | 1908.09% | -46.06% | 0.10 | -48.80 | 7.14 | 6.97 | 0.21 | 6620.00% | — | 6094.00% | -4.73% | -3.09 | 1474.57% | 0.00% | 0.00% | 0.00% | -14.76 | -19.10 | — | 13.58 |
About Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
- CEO
- Kim Kelderman
- Employees
- 3.1K
- Beta
- 1.47
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($21.70 ÷ $55.02) − 1 = -60.56% (DCF, example).